These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10834311)
1. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies. Ito D; Ogasawara K; Matsushita K; Morohashi T; Namba K; Matsuki N; Kitaichi N; Inuyama Y; Hosokawa M; Nakayama E; Iwabuchi K; Onoé K Immunobiology; 2000 Apr; 201(5):527-40. PubMed ID: 10834311 [TBL] [Abstract][Full Text] [Related]
2. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. Ito D; Ogasawara K; Iwabuchi K; Inuyama Y; Onoé K J Immunol; 2000 Feb; 164(3):1230-5. PubMed ID: 10640735 [TBL] [Abstract][Full Text] [Related]
3. CTLA-4 (CD152) inhibits the specific lysis mediated by human cytolytic T lymphocytes in a clonally distributed fashion. Saverino D; Tenca C; Zarcone D; Merlo A; Megiovanni AM; Valle MT; Manca F; Grossi CE; Ciccone E J Immunol; 1999 Jan; 162(2):651-8. PubMed ID: 9916682 [TBL] [Abstract][Full Text] [Related]
4. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
5. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin. Sun W; Wang Q; Zhang L; Liu Y; Zhang M; Wang C; Wang J; Cao X Transplantation; 2003 Nov; 76(9):1351-9. PubMed ID: 14627915 [TBL] [Abstract][Full Text] [Related]
6. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity. Van Gool SW; de Boer M; Ceuppens JL J Immunol; 1993 Apr; 150(8 Pt 1):3254-63. PubMed ID: 7682237 [TBL] [Abstract][Full Text] [Related]
7. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. Croft M; Joseph SB; Miner KT J Immunol; 1997 Oct; 159(7):3257-65. PubMed ID: 9317124 [TBL] [Abstract][Full Text] [Related]
8. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. Gajewski TF J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help. McCoy KD; Hermans IF; Fraser JH; Le Gros G; Ronchese F J Exp Med; 1999 Apr; 189(7):1157-62. PubMed ID: 10190907 [TBL] [Abstract][Full Text] [Related]
10. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Yang YF; Zou JP; Mu J; Wijesuriya R; Ono S; Walunas T; Bluestone J; Fujiwara H; Hamaoka T Cancer Res; 1997 Sep; 57(18):4036-41. PubMed ID: 9307290 [TBL] [Abstract][Full Text] [Related]
11. Human dendritic cells activate T lymphocytes via a CD40: CD40 ligand-dependent pathway. McLellan AD; Sorg RV; Williams LA; Hart DN Eur J Immunol; 1996 Jun; 26(6):1204-10. PubMed ID: 8647193 [TBL] [Abstract][Full Text] [Related]
12. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. Kearney ER; Walunas TL; Karr RW; Morton PA; Loh DY; Bluestone JA; Jenkins MK J Immunol; 1995 Aug; 155(3):1032-6. PubMed ID: 7543510 [TBL] [Abstract][Full Text] [Related]
13. IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. Konieczny BT; Dai Z; Elwood ET; Saleem S; Linsley PS; Baddoura FK; Larsen CP; Pearson TC; Lakkis FG J Immunol; 1998 Mar; 160(5):2059-64. PubMed ID: 9498741 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706 [TBL] [Abstract][Full Text] [Related]
15. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097 [TBL] [Abstract][Full Text] [Related]
16. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells. Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249 [TBL] [Abstract][Full Text] [Related]
17. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]
18. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Zhong RK; Loken M; Lane TA; Ball ED Cytotherapy; 2006; 8(1):3-12. PubMed ID: 16627340 [TBL] [Abstract][Full Text] [Related]